Cytokinetics succeeds where Bristol Myers failed in heart muscle disease

Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The company said Tuesday that Myqorzo ...